One of the most common misconceptions about the July 23, 2026 PCAC meeting is that it is the decision point — that a favorable vote means BPC-157 compounding becomes legal, or that an unfavorable vote means it becomes definitively prohibited. Neither is true. The PCAC vote is one input into a longer, formal process. Here is what actually happens next.
Step 1: FDA reviews the recommendation
After the PCAC vote, FDA staff reviews the committee's recommendation alongside their own analysis, the briefing documents, and any public comments submitted before and during the meeting. The FDA is not required to follow the recommendation but does so in the majority of cases.
This review period has no fixed deadline. The FDA may take weeks or months before deciding how to proceed. During this time, BPC-157's regulatory status does not change.
Step 2: Notice of proposed rulemaking (NPRM)
If the FDA decides to pursue adding BPC-157 to the 503A bulks list following a favorable recommendation, it must publish a notice of proposed rulemaking (NPRM) in the Federal Register. The NPRM:
- Describes the FDA's proposed action (adding BPC-157 to the 503A bulks list)
- Summarizes the supporting rationale and evidence
- Opens a public comment period (typically 60–90 days)
- Solicits input from compounders, healthcare providers, patients, researchers, and other stakeholders
The NPRM is an important public document. Anyone can submit comments — and those comments become part of the administrative record that the FDA must consider in its final decision.
Step 3: Public comment period
During the public comment period, the FDA receives written submissions from anyone who chooses to comment. Comments can support or oppose the proposed rule, provide additional evidence, raise safety concerns, or identify implementation questions.
The FDA is required to read and consider all substantive comments. The agency does not need to adopt every suggestion, but it must respond to significant issues raised in comments.
Step 4: Final rule
After the comment period closes, the FDA reviews all comments, prepares responses, and drafts a final rule. The final rule is published in the Federal Register. Upon its effective date, BPC-157 would be officially placed on the 503A bulks list and legally available for use by licensed 503A compounding pharmacies.
The effective date is typically 30–60 days after publication of the final rule, though it can vary.
How long does this take?
The full rulemaking process — from favorable PCAC recommendation to final rule — has historically taken many months to over a year. There is significant variation depending on FDA staff capacity, the complexity of the substance, and the volume of public comments. Some 503A rulemakings have taken considerably longer.
There is no statutory deadline that requires the FDA to complete the process within any fixed timeframe after a PCAC recommendation. The timeline is driven by agency resources and regulatory priorities.
What if the PCAC recommends against BPC-157?
If the PCAC does not recommend BPC-157 for inclusion on the 503A bulks list, the FDA would typically not initiate rulemaking to add it. The current restricted status would be reinforced. The substance could be re-nominated in the future if new evidence emerged, but there is no automatic re-review timeline.
A negative recommendation would not prohibit new research, clinical trials, or a future NDA application for an approved BPC-157 drug — it would simply mean the compounding pathway is not currently supported by the advisory committee.
BPC157.now will cover every step
We will publish plain-language coverage of each development in this process — NPRM, comment periods, final rules, and any delays or changes. Subscribers get notified within hours of publication. The formal process may be slow, but we will make sure it is understandable.
